Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Rosa Marquez

Physician Assistant, Surgical Dakota Dunes, SD Physician Assistant

NPI 1114524378 CMS profile 11123593

575 N Sioux Point Rd, Dakota Dunes, SD 57049

Open in the dashboard

General payments

$2,513

154 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rosa Marquez of Dakota Dunes, SD is reported in the CMS Open Payments database as having received $2,513 across 154 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $741 42
2024 General $662 42
2023 General $608 37
2022 General $427 28
2021 General $75 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rosa Marquez
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Rosa Marquez were reported at $741. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Rosa Marquez Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $75 $111 $36–$285 $132
2022 $427 $126 $44–$350 $149
2023 $608 $137 $47–$355 $160
2024 $662 $146 $49–$384 $164
2025 $741 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $1,018 79 payments
  2. AbbVie, Inc. $325 17 payments
  3. Janssen Biotech, Inc. $279 11 payments
  4. UCB, Inc. $190 11 payments
  5. AstraZeneca Pharmaceuticals LP $153 7 payments
  6. Novartis Pharmaceuticals Corporation $113 5 payments
  7. Aurinia Pharma U.S., Inc. $102 5 payments
  8. Radius Health, Inc. $82 4 payments
  9. Pfizer Inc. $80 5 payments
  10. Fresenius Kabi USA, LLC $55 3 payments
  11. Other $115 7 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,386 152 payments
  2. Education $127 2 payments
Products named General payments · program years 2021–2025
  1. Otezla $458 40 payments
  2. Enbrel Inflammation $392 31 payments
  3. TREMFYA $279 11 payments
  4. RINVOQ $261 11 payments
  5. TAVNEOS $254 20 payments
  6. Enbrel Inflammation $208 15 payments
  7. COSENTYX $113 5 payments
  8. Cimzia $105 7 payments
  9. LUPKYNIS $102 5 payments
  10. Bimzelx $85 4 payments
  11. Other $545 32 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

1,082

Median for Physician Assistant: 241

Drug cost

$166,265

Median for Physician Assistant: $4,110

Branded share of claims

27.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Taltz Autoinjector Ixekizumab Brand 11 $74,852
Rinvoq Upadacitinib Brand 11 $69,608
Hydroxychloroquine Sulfate Generic 199 $7,040
Methotrexate Methotrexate Sodium Brand 262 $5,407
Leflunomide Generic 43 $3,375
Sulfasalazine Generic 106 $1,592
Prednisone Generic 211 $1,417
Diclofenac Sodium Generic 25 $947
Gabapentin Generic 55 $591
Sulfasalazine Dr Sulfasalazine Brand 16 $527

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$46,086

Medicare's payments for the services billed

Medicare patients

225

Average age 73

Services billed

1,063

149 women, 76 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Chronic kidney disease 25%
Depression 22%
Osteoporosis 21%
Diabetes 20%
COPD 20%
Ischemic heart disease 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Enbrel
  • Amgen Inc. $124
$124 — —
TAVNEOS
  • Amgen Inc. $79
$79 — —
Otezla
  • Amgen Inc. $67
$67 — —
RINVOQ
  • AbbVie, Inc. $61
$61 11 —
COSENTYX
  • Novartis Pharmaceuticals Corporation $49
$49 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

154 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record